Literature DB >> 2625323

17OH-progesterone response to acute dexamethasone administration in congenital adrenal hyperplasia.

S X Shen1, M C Young, M Hinohosa-Sandoval, I A Hughes.   

Abstract

Glucocorticoid-related changes in 17OH-progesterone (17P) concentrations were studied in 13 patients receiving treatment for 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). Blood spot and saliva 17P levels were elevated, with or without loss of diurnal rhythm, within 24 h of stopping maintenance glucocorticoid therapy. A single dose of dexamethasone (0.01 mg/kg) given either intravenously or orally at 09.00 h resulted in rapid onset of complete pituitary-adrenal suppression characterised by a prompt and exponential fall in 17P levels (first-order elimination half-life, mean 2.87 h, range 1.98-3.98 h). Concentrations of 17P remained low throughout the day until the onset of an abrupt nocturnal rise, which occurred between 24.00 and 05.00 h. There were individual differences in both the rate of fall and the timing of the nocturnal rise in 17P levels which may partly explain the need to vary individual steroid requirements in the treatment of CAH.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2625323     DOI: 10.1159/000181275

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  2 in total

1.  Dexamethasone therapy of congenital adrenal hyperplasia and the myth of the "growth toxic" glucocorticoid.

Authors:  Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2010-04-15

2.  Nocturnal Dexamethasone versus Hydrocortisone for the Treatment of Children with Congenital Adrenal Hyperplasia.

Authors:  Andrew Dauber; Henry A Feldman; Joseph A Majzoub
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.